Abstract:
The disease activity threshold necessary to start DMARD
by combined or monotherapy was established arbitrary, for
patient with axial spondyloarthritis, at BASDAI ≥ 4. At the
moment, the correlation between the activity of the disease
and pain, inflammation and the impairment of spinal motor
function. The objection of the study was to systematically
compare the clinical, laboratory and radiological data of
patients with SpAax with the BASDAI index. 100 patients
that haven’t been previously treated with biological drugs
were included in the study.